Introduction to the chemistry and pharmacology of psychedelic drugs
Scott R. Walker
A , Glenn A. Pullella B , Matthew J. Piggott B and Peter J. Duggan A C *
A CSIRO Manufacturing, Research Way, Clayton, Vic. 3168, Australia.
B Chemistry, School of Molecular Sciences, University of Western Australia, Crawley, WA 6009, Australia. Email: matthew.piggott@uwa.edu.au
C College of Science and Engineering, Flinders University, Adelaide, SA 5042, Australia.
Abstract
The science of psychedelics is an intriguing, multi-disciplinary field that has recently been the subject of heightened public interest. This has mainly resulted from publicity associated with a number of high-profile investigations into psychedelic-assisted therapy for a range of difficult-to-treat mental health conditions. With many psychedelic substances known, including natural, semi-synthetic and fully synthetic, and a rangeof receptors, enzymes and transporters implicated in their modes of action, although very interesting, the field can appear daunting to newcomers to the area. This Primer Review is designed to give an overview of the chemistry and pharmacology of psychedelics. It is hoped that it will provide a useful resource for science undergraduates, postgraduates and their instructors, and experienced scientists who require a comprehensive and up-to-date summary of the field. The Review begins with a summary of the important classes of psychedelics and then goes on to summarise the known history of their traditional human use, dating back to prehistoric times. Following that, important classes of psychedelics are examined in more detail, namely the ergolines, such as lysergic acid diethylamide (LSD), tryptamines like psilocybin and N,N-dimethyltryptamine, phenethylamines typified by mescaline and 3,4-methylenedioxymethamphetamine (MDMA), arylcyclohexylamines including ketamine and phenylcyclohexylpiperidine (PCP), and a group of naturally occurring drugs that do not belong to any of these three classes, examples being muscimol and salvinorin A. The contributions made by early pioneers like Albert Hofmann and Alexander Shulgin are briefly summarised. References to primary literature and more specialised reviews are provided throughout.
Keywords: arylcyclohexylamines, ergolines, hallucinogens, natural products chemistry, phenethylamines, psychedelics, receptors, tryptamines.
References
1 Tanne JH. Humphry Osmond. BMJ 2004; 328: 713.
| Crossref | Google Scholar |
2 Nayak SM, Griffiths RR. A single belief-changing psychedelic experience is associated with increased attribution of consciousness to living and non-living entities. Front Psychol 2022; 13: 852248.
| Crossref | Google Scholar |
3 MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 2011; 25: 1453-1461.
| Crossref | Google Scholar |
4 Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. Increased global integration in the brain after psilocybin therapy for depression. Nat Med 2022; 28: 844-851.
| Crossref | Google Scholar |
5 Duggan PJ. The chemistry of cannabis and cannabinoids. Aust J Chem 2021; 74: 369-387.
| Crossref | Google Scholar |
6 Voynova M, Shkondrov A, Kondeva-Burdina M, Krasteva I. Toxicological and pharmacological profile of Amanita muscaria (L.) Lam. – a new rising opportunity for biomedicine. Pharmacia 2020; 67: 317-323.
| Crossref | Google Scholar |
8 Berlant SR. The entheomycological origin of Egyptian crowns and the esoteric underpinnings of Egyptian religion. J Ethnopharmacol 2005; 102: 275-288.
| Crossref | Google Scholar |
9 Cassels BK, Sáez-Briones P. Dark classics in chemical neuroscience: Mescaline. ACS Chem Neurosci 2018; 9: 2448-2458.
| Crossref | Google Scholar |
10 Brito-da-Costa AM, Dias-da-Silva D, Gomes NGM, Dinis-Oliveira RJ, Madureira-Carvalho Á. Toxicokinetics and toxicodynamics of ayahuasca alkaloids N,N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine: Clinical and forensic impact. Pharmaceuticals 2020; 13: 334.
| Crossref | Google Scholar |
11 Moretti C, Gaillard Y, Grenand P, Bévalot F, Prévosto J-M. Identification of 5-hydroxy-tryptamine (bufotenine) in takini (Brosimum acutifolium Huber subsp. acutifolium C.C. Berg, Moraceae), a shamanic potion used in the Guiana Plateau. J Ethnopharmacol 2006; 106: 198-202.
| Crossref | Google Scholar |
12 Schwelm HM, Zimmermann N, Scholl T, Penner J, Autret A, Auwärter V, Neukamm MA. Qualitative and quantitative analysis of tryptamines in the poison of Incilius alvarius (Amphibia: Bufonidae). J Anal Toxicol 2022; 46: 540-548.
| Crossref | Google Scholar |
13 Davis W, Weil AT. Identity of a New World psychoactive toad. Anc Mesoam 1992; 3: 51-59.
| Crossref | Google Scholar |
14 Jensen H, Chen KK. The chemical identity of certain basic constituents present in the secretions of various species of toads. J Biol Chem 1936; 116: 87-91.
| Crossref | Google Scholar |
15 Hernández-Alvarado RB, Madariaga-Mazón A, Ortega A, Martinez-Mayorga K. Dark classics in chemical neuroscience: Salvinorin A. ACS Chem Neurosci 2020; 11: 3979-3992.
| Crossref | Google Scholar |
16 Jenks C. Extraction studies of Tabernanthe Iboga and Voacanga Africana. Nat Prod Lett 2002; 16: 71-76.
| Crossref | Google Scholar |
17 Wasko MJ, Witt-Enderby PA, Surratt CK. Dark classics in chemical neuroscience: Ibogaine. ACS Chem Neurosci 2018; 9: 2475-2483.
| Crossref | Google Scholar |
18 Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol 2008; 115: 9-24.
| Crossref | Google Scholar |
19 Paulke A, Kremer C, Wunder C, Wurglics M, Schubert-Zsilavecz M, Toennes SW. Studies on the alkaloid composition of the Hawaiian Baby Woodrose Argyreia nervosa, a common legal high. Forensic Sci Int 2015; 249: 281-293.
| Crossref | Google Scholar |
20 Smakosz A, Kurzyna W, Rudko M, Dąsal M. The usage of ergot (Claviceps purpurea (fr.) Tul.) in obstetrics and gynecology: A historical perspective. Toxins 2021; 13: 492.
| Crossref | Google Scholar |
21 Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Pharmacol Therapeut 2019; 197: 83-102.
| Crossref |
22 Steiner U, Ahimsa-Müller MA, Markert A, Kucht S, Groß J, Kauf N, Kuzma M, Zych M, Lamshöft M, Furmanowa M, Knoop V, Drewke C, Leistner E. Molecular characterization of a seed transmitted clavicipitaceous fungus occurring on dicotyledoneous plants (Convolvulaceae). Planta 2006; 224: 533-544.
| Crossref | Google Scholar |
23 Steiner U, Leistner E. Ergot alkaloids and their hallucinogenic potential in morning glories. Planta Med 2018; 84: 751-758.
| Crossref | Google Scholar |
24 Eady C. The impact of alkaloid-producing Epichloë endophyte on forage ryegrass breeding: A New Zealand perspective. Toxins 2021; 13: 158.
| Crossref | Google Scholar |
25 Blaney BJ, Molloy JB, Brock IJ. Alkaloids in Australian rye ergot (Claviceps purpurea) sclerotia: implications for food and stockfeed regulations. Anim Prod Sci 2009; 49: 975-982.
| Crossref | Google Scholar |
26 Uhlig S, Rangel-Huerta OD, Divon HH, Rolén E, Pauchon K, Sumarah MW, Vrålstad T, Renaud JB. Unraveling the ergot alkaloid and indole diterpenoid metabolome in the Claviceps purpurea species complex using LC–HRMS/MS diagnostic fragmentation filtering. J Agric Food Chem 2021; 69: 7137-7148.
| Crossref | Google Scholar |
27 Chao JM, Der Marderosian AH. Ergoline alkaloidal constituents of Hawaiian Baby Wood Rose, Argyreia nervosa (Burm. f.) Bojer. J Pharm Sci 1973; 62: 588-591.
| Crossref | Google Scholar |
28 Kucht S, Groß J, Hussein Y, Grothe T, Keller U, Basar S, König WA, Steiner U, Leistner E. Elimination of ergoline alkaloids following treatment of Ipomoea asarifolia (Convolvulaceae) with fungicides. Planta 2004; 219: 619-625.
| Crossref | Google Scholar |
29 Li S-M, Unsöld I. Post-genome research on the biosynthesis of ergot alkaloids. Planta Med 2006; 72: 1117-1120.
| Crossref | Google Scholar |
30 Markert A, Steffan N, Ploss K, Hellwig S, Steiner U, Drewke C, Li S-M, Boland W, Leistner E. Biosynthesis and accumulation of ergoline alkaloids in a mutualistic association between Ipomoea asarifolia (Convolvulaceae) and a Clavicipitalean fungus. Plant Physiol 2008; 147: 296-305.
| Crossref | Google Scholar |
32 Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: A review. CNS Neurosci Ther 2008; 14: 295-314.
| Crossref | Google Scholar |
33 Hofmann A, Heim R, Brack A, Kobel H. Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim. Experientia 1958; 14: 107-109.
| Crossref | Google Scholar |
34 Ortega A, Blount JF, Manchand PS. Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum(Labiatae). J Chem Soc Perkin Trans 1 1982; 2505-2508.
| Crossref | Google Scholar |
35 Schiff Jr PL. Ergot and its alkaloids. Am J Pharm Educ 2006; 70: 98.
| Crossref | Google Scholar |
36 Ott J, Neely P. Entheogenic (hallucinogenic) effects of methylergonovine. J Psychedelic Drugs 1980; 12: 165-166.
| Crossref | Google Scholar |
38 Wong G, Lim LR, Tan YQ, Go MK, Bell DJ, Freemont PS, Yew WS. Reconstituting the complete biosynthesis of D-lysergic acid in yeast. Nat Commun 2022; 13: 712.
| Crossref | Google Scholar |
39 Wallwey C, Li SM. Ergot alkaloids: structure diversity, biosynthetic gene clusters and functional proof of biosynthetic genes. Nat Prod Rep 2011; 28: 496-510.
| Crossref | Google Scholar |
40 Arnold G, Gasser T, Storch A, Lipp A, Kupsch A, Hundemer HP, Schwarz J. High doses of pergolide improve clinical global impression in advanced Parkinson's disease—A preliminary open label study. Arch Gerontol Geriatr 2005; 41: 239-253.
| Crossref | Google Scholar |
41 Tsuboi T, Watanabe H, Katsuno M, Sobue G. Cabergoline in the treatment of Parkinson’s disease. In: Riederer P, Laux G, Mulsant B, Le W, Nagatsu T, editors. NeuroPsychopharmacotherapy. Springer; 2019. pp. 1–10. https://doi.org/10.1007/978-3-319-56015-1_223-1
42 Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinet 2017; 56: 1219-1230.
| Crossref | Google Scholar |
44 Gurevich VV, Gurevich EV. GPCR signaling regulation: The role of GRKs and arrestins. Front Pharmacol 2019; 10: 125.
| Crossref | Google Scholar |
45 Janowsky A, Eshleman AJ, Johnson RA, Wolfrum KM, Hinrichs DJ, Yang J, Zabriskie TM, Smilkstein MJ, Riscoe MK. Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro. Psychopharmacology 2014; 231: 2771-2783.
| Crossref | Google Scholar |
46 Wacker D, Wang S, McCorvy JD, Betz RM, Venkatakrishnan AJ, Levit A, Lansu K, Schools ZL, Che T, Nichols DE, Shoichet BK, Dror RO, Roth BL. Crystal structure of an LSD-bound human serotonin receptor. Cell 2017; 168: 377-389.e12.
| Crossref | Google Scholar |
47 Karaki S, Becamel C, Murat S, Mannoury la Cour C, Millan MJ, Prézeau L, Bockaert J, Marin P, Vandermoere F. Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists. Mol Cell Proteomics 2014; 13: 1273-1285.
| Crossref | Google Scholar |
48 Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven AB, Nichols DE, Shoichet BK, Skiniotis G, Roth BL. Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell 2020; 182: 1574-1588.e19.
| Crossref | Google Scholar |
49 Cao D, Yu J, Wang H, Luo Z, Liu X, He L, Qi J, Fan L, Tang L, Chen Z, Li J, Cheng J, Wang S. Structure-based discovery of nonhallucinogenic psychedelic analogs. Science 2022; 375: 403-411.
| Crossref | Google Scholar |
50 Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M. Pharmacological characterisation of the agonist radioligand binding site of 5-HT2A, 5-HT2B and 5-HT2C receptors. Naunyn Schmiedebergs Arch Pharmacol 2004; 370: 114-123.
| Crossref | Google Scholar |
51 Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci 2021; 30: 70-82.
| Crossref | Google Scholar |
52 Stierand K, Maaß PC, Rarey M. Molecular complexes at a glance: automated generation of two-dimensional complex diagrams. Bioinformatics 2006; 22: 1710-1716.
| Crossref | Google Scholar |
53 Hoffman AJ, Nichols DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. J Med Chem 1985; 28: 1252-1255.
| Crossref | Google Scholar |
55 Barker SA, McIlhenny EH, Strassman R. A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955–2010. Drug Test Anal 2012; 4: 617-635.
| Crossref | Google Scholar |
56 Dean JG, Liu T, Huff S, Sheler B, Barker SA, Strassman RJ, Wang MM, Borjigin J. Biosynthesis and extracellular concentrations of N,N-dimethyltryptamine (DMT) in mammalian brain. Sci Rep 2019; 9: 9333.
| Crossref | Google Scholar |
57 Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 2003; 306: 73-83.
| Crossref | Google Scholar |
58 Reynolds HT, Vijayakumar V, Gluck-Thaler E, Korotkin HB, Matheny PB, Slot JC. Horizontal gene cluster transfer increased hallucinogenic mushroom diversity. Evol Lett 2018; 2: 88-101.
| Crossref | Google Scholar |
59 Schmull M, Dal-Forno M, Lücking R, Cao S, Clardy J, Lawrey JD. Dictyonema huaorani (Agaricales: Hygrophoraceae), a new lichenized basidiomycete from Amazonian Ecuador with presumed hallucinogenic properties. Bryologist 2014; 117: 386-394.
| Crossref | Google Scholar |
60 Lenz C, Wick J, Braga D, García-Altares M, Lackner G, Hertweck C, Gressler M, Hoffmeister D. Injury-triggered blueing reactions of Psilocybe “magic” mushrooms. Angew Chem Int Ed 2020; 59: 1450-1454.
| Crossref | Google Scholar |
61 Gotvaldova K, Borovička J, Hájková K, Cihlářová P, Rockefeller A, Kuchař M. Extensive collection of psychotropic mushrooms with determination of their tryptamine alkaloids. Int J Mol Sci 2022; 23: 14068.
| Crossref | Google Scholar |
62 Gartz J. Biotransformation of tryptamine derivatives in mycelial cultures of Psilocybe. J Basic Microbiol 1989; 29: 347-352.
| Crossref | Google Scholar |
63 Glatfelter GC, Pottie E, Partilla JS, Sherwood AM, Kaylo K, Pham DNK, Naeem M, Sammeta VR, DeBoer S, Golen JA, Hulley EB, Stove CP, Chadeayne AR, Manke DR, Baumann MH. Structure–activity relationships for psilocybin, baeocystin, aeruginascin, and related analogues to produce pharmacological effects in mice. ACS Pharmacol Transl Sci 2022; 5: 1181-1196.
| Crossref | Google Scholar |
64 Roth BL, Lopez E, Patel S, Kroeze WK. The multiplicity of serotonin receptors: Uselessly diverse molecules or an embarrassment of riches? Neuroscientist 2000; 6: 252-262.
| Crossref | Google Scholar |
65 Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, Cameron LP, Patel SD, Hennessey JJ, Saeger HN, McCorvy JD, Gray JA, Tian L, Olson DE. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 2023; 379: 700-706.
| Crossref | Google Scholar |
66 Schmid CL, Bohn LM. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a β-arrestin2/Src/Akt signaling complex in vivo. J Neurosci 2010; 30: 13513-13524.
| Crossref | Google Scholar |
67 Xu P, Huang S, Zhang H, Mao C, Zhou XE, Cheng X, Simon IA, Shen DD, Yen HY, Robinson CV, Harpsøe K, Svensson B, Guo J, Jiang H, Gloriam DE, Melcher K, Jiang Y, Zhang Y, Xu HE. Structural insights into the lipid and ligand regulation of serotonin receptors. Nature 2021; 592: 469-473.
| Crossref | Google Scholar |
68 Bernschneider-Reif S, Öxler F, Freudenmann RW. The origin of MDMA (‘ecstasy’) – separating the facts from the myth. Pharmazie 2006; 61: 966-972.
| Google Scholar |
69 Bruhn JG, EI-Seedi HR, Stephanson N, Beck O, Shulgin AT. Ecstasy analogues found in cacti. J Psychoactive Drugs 2008; 40: 219-222.
| Crossref | Google Scholar |
70 Dunlap LE, Andrews AM, Olson DE. Dark classics in chemical neuroscience: 3,4-methylenedioxymethamphetamine. ACS Chem Neurosci 2018; 9: 2408-2427.
| Crossref | Google Scholar |
71 Sessa B. Why MDMA therapy for alcohol use disorder? And why now? Neuropharmacology 2018; 142: 83-88.
| Crossref | Google Scholar |
72 Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 2019; 204: 107402.
| Crossref | Google Scholar |
73 Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot’alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med 2021; 27: 1025-1033.
| Crossref | Google Scholar |
75 Klein MT, Kalam M, Trout K, Fowler N, Terry M. Mescaline concentrations in three principal tissues of Lophophora williamsii (Cactaceae): Implications for sustainable harvesting practices. Haseltonia 2015; 2015: 34-42.
| Crossref | Google Scholar |
76 Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: Clinical and forensic repercussions. Curr Mol Pharmacol 2019; 12: 184-194.
| Crossref | Google Scholar |
77 Späth E. Über dieanhalonium-alkaloide. Monatsh Chem 1919; 40: 129-154.
| Crossref | Google Scholar |
78 Jay M. ‘Sartre’s Bad Trip’, The Paris Review. 2019. Available at https://www.theparisreview.org/blog/2019/08/21/sartres-bad-trip/ [verified 15 February 2023].
80 Last A. The History Hour: Why a British MP was filmed taking mescaline. BBC, 2021. Available at https://www.bbc.co.uk/programmes/w3ct1z6v [verified 15 February 2023].
81 Guttmann E. Artificial psychoses produced by mescaline. J Ment Sci 1936; 82: 203-221.
| Crossref | Google Scholar |
82 Vamvakopoulou IA, Narine KAD, Campbell I, Dyck JRB, Nutt DJ. Mescaline: The forgotten psychedelic. Neuropharmacology 2023; 222: 109294.
| Crossref | Google Scholar |
83 Osmond H, Smythies J. Schizophrenia: A new approach. J Ment Sci 1952; 98: 309-315.
| Crossref | Google Scholar |
84 Denber HCB, Merlis S. Studies on mescaline I. Action in schizophrenic patients. Psychiatr Q 1955; 29: 421-429.
| Crossref | Google Scholar |
86 Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 2016; 26: 1327-1337.
| Crossref | Google Scholar |
87 Miller GM. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem 2011; 116: 164-176.
| Crossref | Google Scholar |
88 Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME. Receptor interaction profiles of 4-alkoxy-3,5-dimethoxy-phenethylamines (mescaline derivatives) and related amphetamines. Front Pharmacol 2022; 12: 794254.
| Crossref | Google Scholar |
89 Agin-Liebes G, Haas TF, Lancelotta R, Uthaug MV, Ramaekers JG, Davis AK. Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacol Transl Sci 2021; 4: 543-552.
| Crossref | Google Scholar |
90 Uthaug MV, Davis AK, Haas TF, Davis D, Dolan SB, Lancelotta R, Timmermann C, Ramaekers JG. The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. J Psychopharmacol 2022; 36: 309-320.
| Crossref | Google Scholar |
91 Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984; 35: 2505-2511.
| Crossref | Google Scholar |
92 Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE. A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. J Med Chem 1998; 41: 5148-5149.
| Crossref | Google Scholar |
93 Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 2006; 70: 1956-1964.
| Crossref | Google Scholar |
94 Glennon RA, Dukat M, El-Bermawy M, Law H, De Los Angeles J, Teitler M, King A, Herrick-Davis K. Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines. J Med Chem 1994; 37: 1929-1935.
| Crossref | Google Scholar |
95 Nichols DE. Structure–activity relationships of serotonin 5-HT2A agonists. WIREs Membr Transp Signal 2012; 1: 559-579.
| Crossref | Google Scholar |
96 Jacob III P, Shulgin AT. Sulfur analogs of psychotomimetic agents. 2. Analogs of (2,5-dimethoxy-4-methylphenyl)- and of (2,5-dimethoxy-4-ethylphenyl)isopropylamine. J Med Chem 1983; 26: 746-752.
| Crossref | Google Scholar |
97 Cunningham MJ, Bock HA, Serrano IC, Bechand B, Vidyadhara DJ, Bonniwell EM, Lankri D, Duggan P, Nazarova AL, Cao AB, Calkins MM, Khirsariya P, Hwu C, Katritch V, Chandra SS, McCorvy JD, Sames D. Pharmacological mechanism of the non-hallucinogenic 5-HT2A agonist ariadne and analogs. ACS Chem Neurosci 2023; 14: 119-135.
| Crossref | Google Scholar |
98 Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, Kristensen JL. Synthesis and structure–activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chem Neurosci 2014; 5: 243-249.
| Crossref | Google Scholar |
99 Hansen M, Jacobsen SE, Plunkett S, Liebscher GE, McCorvy JD, Bräuner-Osborne H, Kristensen JL. Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists. Biorg Med Chem 2015; 23: 3933-3937.
| Crossref | Google Scholar |
101 Poulie CBM, Jensen AA, Halberstadt AL, Kristensen JL. Dark classics in chemical neuroscience: NBOMes. ACS Chem Neurosci 2020; 11: 3860-3869.
| Crossref | Google Scholar |
102 Isberg V, Paine J, Leth-Petersen S, Kristensen JL, Gloriam DE. Structure-activity relationships of constrained phenylethylamine ligands for the serotonin 5-HT2 receptors. PLoS One 2013; 8: e78515.
| Crossref | Google Scholar |
103 Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101: 131-181.
| Crossref | Google Scholar |
104 Nichols DE. Psychedelics. Pharmacol Rev 2016; 68: 264-355.
| Crossref | Google Scholar |
105 Glennon RA. The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The “phenylalkylaminome” with a focus on selected drugs of abuse. J Med Chem 2017; 60: 2605-2628.
| Crossref | Google Scholar |
107 Chewy. ‘It Almost Killed Me: An Experience with 25I-NBOMe (exp95622)’, Erowid. 2012. Available at https://erowid.org/experiences/exp.php?ID=95622 [verified 25 February 2023].
108 Krasowski S. Poisons Standard February 2022. Australian Federal Department of Health and Aged Care; 2022. Available at https://www.legislation.gov.au/Series/F2022L00074 [verified 25 February 2023].
109 Benzenhöfer U, Passie T. Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction 2010; 105: 1355-1361.
| Crossref | Google Scholar |
112 Passie T. The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985). Drug Sci Policy Law 2018; 4: 205032451876744.
| Crossref | Google Scholar |
113 Australian Institute of Health and Welfare. Illicit Drug Use. Canberra: AIHW; 2022. Available at https://www.aihw.gov.au/reports/illicit-use-of-drugs/illicit-drug-use [verified 19 February 2023].
114 Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: Entactogens. J Psychoactive Drugs 1986; 18: 305-313.
| Crossref | Google Scholar |
115 Winter JC. Effects of the phenethylamine derivatives, BL-3912, fenfluramine, and Sch-12679, in rats trained with LSD as a discriminative stimulus. Psychopharmacology 1980; 68: 159-162.
| Crossref | Google Scholar |
116 Freudenmann RW, Spitzer M. The neuropsychopharmacology and toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). CNS Drug Rev 2004; 10: 89-116.
| Crossref | Google Scholar |
119 Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, Yong‐Kee CJ, Gandy MN, McIldowie M, Lewis KD, Gomez‐Ramirez J, Lee J, Fox SH, Martin‐Iverson M, Nash JE, Piggott MJ, Brotchie JM. A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances l-DOPA benefit in parkinsonian primates. FASEB J 2012; 26: 2154-2163.
| Crossref | Google Scholar |
120 Oeri HE. Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy. J Psychopharmacol 2021; 35: 512-536.
| Crossref | Google Scholar |
121 Marona-Lewicka D, Rhee G-S, Sprague JE, Nichols DE. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol Biochem Behav 1996; 53: 99-105.
| Crossref | Google Scholar |
122 Nichols DE. Entactogens: How the name for a novel class of psychoactive agents originated. Front Psychiatry 2022; 13: 863088.
| Crossref | Google Scholar |
124 Parrott AC. Oxytocin, cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of recreational ‘ecstasy’. Behav Pharmacol 2016; 27: 649-658.
| Crossref | Google Scholar |
125 Multidisciplinary Association for Psychedelic Studies. MDMA-Assisted Therapy for PTSD. 2023. Available at https://maps.org/mdma/ptsd/ [verified 25 February 2023].
126 Oehen P, Gasser P. Using a MDMA- and LSD-group therapy model in clinical practice in Switzerland and highlighting the treatment of trauma-related disorders. Front Psychiatry 2022; 13: 863552.
| Crossref | Google Scholar |
127 Therapeutic Goods Administration. Notice of final decisions to amend (or not amend) the current Poisons Standard in relation to psilocybine and MDMA. Australian Government Department of Health and Aged Care; 2023. Available at https://www.tga.gov.au/resources/publication/scheduling-decisions-final/notice-final-decision-amend-or-not-amend-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma [verified 25 February 2023].
128 Molliver ME, Berger UV, Mamounas LA, Molliver DC, O’Hearn E, Wilson MA. Neurotoxicity of MDMA and related compounds: Anatomic studies. Ann N Y Acad Sci 1990; 600: 640-661.
| Crossref | Google Scholar |
129 Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther 2011; 90: 246-255.
| Crossref | Google Scholar |
131 Bertron JL, Seto M, Lindsley CW. Dark classics in chemical neuroscience: Phencyclidine (PCP). ACS Chem Neurosci 2018; 9: 2459-2474.
| Crossref | Google Scholar |
132 Morris H, Wallach J. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 2014; 6: 614-632.
| Crossref | Google Scholar |
133 Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20: 201-225.
| Crossref | Google Scholar |
134 Roth BL, Gibbons S, Arunotayanun W, Huang X-P, Setola V, Treble R, Iversen L. The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 2013; 8: e59334.
| Crossref | Google Scholar |
135 Stevens CL, Klundt IL, Munk ME, Pillai MD. Amino ketone rearrangements. IV. Thermal rearrangements of α-amino methyl ketones. J Org Chem 1965; 30: 2967-2972.
| Crossref | Google Scholar |
136 Tyler MW, Yourish HB, Ionescu DF, Haggarty SJ. Classics in chemical neuroscience: Ketamine. ACS Chem Neurosci 2017; 8: 1122-1134.
| Crossref | Google Scholar |
137 Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJA, Curran HV. Journey through the K-hole: Phenomenological aspects of ketamine use. Drug Alcohol Depend 2008; 95: 219-229.
| Crossref | Google Scholar |
138 Jansen K. Near death experience and the NMDA receptor. BMJ 1989; 298: 1708.
| Crossref | Google Scholar |
139 Hartvig P, Valtysson J, Lindner K-J, Kristensen J, Karlsten R, Gustafsson LL, Persson J, Svensson JO, Øye I, Antoni G, Westerberg G, Långström B. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther 1995; 58: 165-173.
| Crossref | Google Scholar |
140 Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KSS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate Jr CA, Gould TD. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016; 533: 481-486.
| Crossref | Google Scholar |
141 Rolland B, Jardri R, Amad A, Thomas P, Cottencin O, Bordet R. Pharmacology of hallucinations: Several mechanisms for one single symptom? BioMed Res Int 2014; 2014: 307106.
| Crossref | Google Scholar |
142 Dunk CW, Lebel T, Keane PJ. Characterisation of ectomycorrhizal formation by the exotic fungus Amanita muscaria with Nothofagus cunninghamii in Victoria, Australia. Mycorrhiza 2012; 22: 135-147.
| Crossref | Google Scholar |
143 Flament E, Guitton J, Gaulier J-M, Gaillard Y. Human poisoning from poisonous higher fungi: Focus on analytical toxicology and case reports in forensic toxicology. Pharmaceuticals 2020; 13: 454.
| Crossref | Google Scholar |
145 Tsai M‐J, Huang Y‐B, Wu P‐C. A novel clinical pattern of visual hallucination after zolpidem use. J Toxicol Clin Toxic 2003; 41: 869-872.
| Crossref | Google Scholar |
146 Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB. Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist. Proc Natl Acad Sci 2002; 99: 11934-11939.
| Crossref | Google Scholar |
148 Timmermann C, Roseman L, Williams L, Erritzoe D, Martial C, Cassol H, Laureys S, Nutt D, Carhart-Harris R. DMT models the near-death experience. Front Psychol 2018; 9: 1424.
| Crossref | Google Scholar |
150 Frolov RV, Ignatova II, Singh S. Inhibition of hERG potassium channels by celecoxib and its mechanism. PLoS One 2011; 6: e26344.
| Crossref | Google Scholar |
151 Straub CJ, Rusali LE, Kremiller KM, Riley AP. What we have gained from ibogaine: α3β4 Nicotinic acetylcholine receptor inhibitors as treatments for substance use disorders. J Med Chem 2023; 66: 107-121.
| Crossref | Google Scholar |
